'Merck KGaA: Phase III Trials of Xevinapant in Locally Advanced Head & Neck Cancer Discontinued'
'Merck KGaA: Phase III Trials of Xevinapant in Locally Advanced Head & Neck Cancer Discontinued'
Xevinapant is currently under clinical investigation and not approved for any indication anywhere in the world.| Merck KGaA / Key word(s): Study results Merck KGaA: Phase III trials of xevinapant in locally advanced head & neck cancer discontinued 24-Jun-2024 / 19:00 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. |
| 默沙東股份有限公司/關鍵詞：研究結果 默沙東：關於xevinapant用於局部晚期頭頸癌的III期臨床試驗已被停止 2024年6月24日/19:00（歐洲中央時區/歐洲中央夏令時） 根據歐盟第596/2014號法規的第17條MAR披露內幕信息，EQS新聞通訊社（EQS Group AG）轉發了此信息。 發行人對此公告的內容單獨負責。 |
Disclosure of inside information pursuant to Article 17 of Regulation (EU) No 596/2014
根據歐盟第596/2014號法規第17條披露內幕信息
Merck KGaA: Phase III trials of xevinapant in locally advanced head & neck cancer discontinued
默沙東：關於xevinapant用於局部晚期頭頸癌的III期臨床試驗已被停止
Darmstadt, June 24, 2024: Merck KGaA is investigating a treatment of xevinapant plus platinum-based chemotherapy (CRT), compared to placebo plus CRT, in patients with unresected locally advanced head and neck cancer in a phase III clinical trial (TrilynX). The company decided to discontinue this study. The decision follows a pre-planned interim analysis performed by the study's Independent Data Monitoring Committee, which found that the trial would be unlikely to meet its primary objective of prolonging event-free survival. Given the totality of the data, the company decided to also stop the phase III clinical trial X-Ray Vision (xevinapant plus radiotherapy, compared to placebo plus radiotherapy in patients who underwent resection of locally advanced head and neck cancer).
默沙東於2024年6月24日宣佈，其正在進行一項III期臨床試驗（TrilynX），將xevinapant聯合鉑金化療（CRT）與安慰劑聯合CRT用於未切除的局部晚期頭頸癌患者的治療進行探究。公司決定停止該研究，該決定是根據研究的獨立數據監測委員會進行的預定中期分析結果，該分析發現該試驗不太可能達到其延長事件無進展生存期的主要目標。鑑於數據的總體情況，公司決定也停止xevinapant聯合放療與安慰劑聯合放療的III期臨床試驗（X-Ray Vision），該試驗是針對已行局部晚期頭頸癌切除的患者而進行的。
Xevinapant is currently under clinical investigation and not approved for any indication anywhere in the world.
xevinapant目前正在接受臨床研究，尚未在全球任何地方獲得批准用於任何適應症。
Esther Döringer
Merck KGaA
Frankfurter Straße 250
64293 Darmstadt
Germany
Phone: +49 151 1454 7809
Email: esther.doeringer@merckgroup.com
Internet:
ISIN: DE0006599905
WKN: 659990
Indices: DAX
Esther Döringer
默沙東股份有限公司。
法蘭克福街250號
64293達姆施塔特
德國
電話：+49 151 1454 7809
電子郵件：esther.doeringer@merckgroup.com
互聯網:
ISIN：DE0006599905
WKN：659990
指數：DAX